1. Home
  2. ITRM vs BLFY Comparison

ITRM vs BLFY Comparison

Compare ITRM & BLFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ITRM
  • BLFY
  • Stock Information
  • Founded
  • ITRM 2015
  • BLFY 1939
  • Country
  • ITRM Ireland
  • BLFY United States
  • Employees
  • ITRM N/A
  • BLFY N/A
  • Industry
  • ITRM Biotechnology: Pharmaceutical Preparations
  • BLFY Commercial Banks
  • Sector
  • ITRM Health Care
  • BLFY Finance
  • Exchange
  • ITRM Nasdaq
  • BLFY Nasdaq
  • Market Cap
  • ITRM 40.0M
  • BLFY 204.2M
  • IPO Year
  • ITRM 2018
  • BLFY N/A
  • Fundamental
  • Price
  • ITRM $0.96
  • BLFY $9.87
  • Analyst Decision
  • ITRM Strong Buy
  • BLFY Hold
  • Analyst Count
  • ITRM 2
  • BLFY 2
  • Target Price
  • ITRM $7.00
  • BLFY $11.00
  • AVG Volume (30 Days)
  • ITRM 532.9K
  • BLFY 61.2K
  • Earning Date
  • ITRM 08-13-2025
  • BLFY 07-23-2025
  • Dividend Yield
  • ITRM N/A
  • BLFY N/A
  • EPS Growth
  • ITRM N/A
  • BLFY N/A
  • EPS
  • ITRM N/A
  • BLFY N/A
  • Revenue
  • ITRM N/A
  • BLFY $41,228,000.00
  • Revenue This Year
  • ITRM N/A
  • BLFY $20.14
  • Revenue Next Year
  • ITRM $270.19
  • BLFY $20.20
  • P/E Ratio
  • ITRM N/A
  • BLFY N/A
  • Revenue Growth
  • ITRM N/A
  • BLFY N/A
  • 52 Week Low
  • ITRM $0.81
  • BLFY $8.34
  • 52 Week High
  • ITRM $3.02
  • BLFY $11.48
  • Technical
  • Relative Strength Index (RSI)
  • ITRM 44.42
  • BLFY 65.11
  • Support Level
  • ITRM $0.93
  • BLFY $9.25
  • Resistance Level
  • ITRM $1.03
  • BLFY $8.94
  • Average True Range (ATR)
  • ITRM 0.04
  • BLFY 0.26
  • MACD
  • ITRM -0.00
  • BLFY 0.11
  • Stochastic Oscillator
  • ITRM 26.15
  • BLFY 95.47

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

Share on Social Networks: